上海交通大学学报(医学版) ›› 2021, Vol. 41 ›› Issue (3): 386-390.doi: 10.3969/j.issn.1674-8115.2021.03.018

• 综述 • 上一篇    下一篇

促进脐血造血干/祖细胞植入策略的研究进展

宁柳心(), 郝思国()   

  1. 上海交通大学医学院附属新华医院血液科,上海 200092
  • 收稿日期:2020-01-15 出版日期:2021-03-28 发布日期:2021-04-06
  • 通讯作者: 郝思国 E-mail:nlx2108@163.com;haosiguo@xinhuamed.com.cn
  • 作者简介:宁柳心(1994—),女,硕士生;电子信箱:nlx2108@163.com
  • 基金资助:
    上海申康医院发展中心市级医院临床技能与临床创新三年行动计划项目(16CR1033B)

Progress in researches on improving engraftment of hematopoietic stem/progenitor cells of cord blood

Liu-xin NING(), Si-guo HAO()   

  1. Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Received:2020-01-15 Online:2021-03-28 Published:2021-04-06
  • Contact: Si-guo HAO E-mail:nlx2108@163.com;haosiguo@xinhuamed.com.cn
  • Supported by:
    Three-year Action Plan for Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shenkang Hospital Development Center(16CR1033B)

摘要:

脐血移植(cord blood transplantation,CBT)已广泛地应用于儿童及成人恶性及非恶性血液病的治疗。与其他来源的造血干/祖细胞移植相比,行CBT后造血系统及免疫系统重建较缓慢且存在一定的植入失败率,从而增加了患者感染等导致的移植相关死亡率。因此,如何促进脐血造血干/祖细胞的植入是CBT多年来研究的热点。该文就近年来在促进脐血造血干/祖细胞植入策略的研究进展方面作一综述。

关键词: 脐血移植, 造血干/祖细胞, 体外扩增, 植入, 归巢

Abstract:

Cord blood transplantation (CBT) has been widely used in the treatment of hematologic malignancies and non-malignant hematologic diseases both in children and adults. Compared with other sources of hematopoietic stem/progenitor cell (HSPC) transplantation, CBT has a higher rate of engraftment failure and delayed hematopoietic system and immune system recovery, thereby increasing the mortality caused by infection and other transplant-related complications. Therefore, how to promote the engraftment of cord blood HSPC has been a hot spot in CBT for many years. The article reviews the latest advances in the strategies to improve the engraftment of HSPC of cord blood.

Key words: cord blood transplantation (CBT), hematopoietic stem/progenitor cell (HSPC), in vitro expansion, engraftment, homing

中图分类号: